Skip to main content

Biological Aspects of DNA Damage by Crosslinking Agents

  • Chapter
Molecular Aspects of Anti-Cancer Drug Action

Part of the book series: Topics in Molecular and Structural Biology ((TMSB))

  • 27 Accesses

Abstract

Since the earliest successes in cancer chemotherapy, which began with the clinical trial of nitrogen mustard (Gilman and Philips, 1946), it was realised that there is something special about compounds having two or more functional groups. As the chemical mechanism of alkylation became clear, it was surmised that the antitumour alkylating agents produce toxic effects due to the formation of covalent crosslinks. By the 1950s, it was suspected that DNA might be the crucial target of crosslinking (Goldacre et al., 1949; Stacey et al., 1958). The model of DNA as a double helix and its role in replication, together with the finding that alkylation can occur on the ring nitrogens of the bases (Brookes and Lawley, 1960, 1961), suggested interstrand crosslinking as a possibly crucial effect, and this phenomenon was soon demonstrated in purified DNA and in cells (Geiduschek, 1961; Iyer and Szybalski, 1963; Kohn et al., 1965, 1966).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

Download references

Authors

Editor information

Editors and Affiliations

Copyright information

© 1983 The Contributors

About this chapter

Cite this chapter

Kohn, K.W. (1983). Biological Aspects of DNA Damage by Crosslinking Agents. In: Neidle, S., Waring, M.J. (eds) Molecular Aspects of Anti-Cancer Drug Action. Topics in Molecular and Structural Biology. Palgrave, London. https://doi.org/10.1007/978-1-349-06010-8_10

Download citation

Publish with us

Policies and ethics